The clinical course of ulcerative colitis after orthotopic liver transplantation for primary sclerosing cholangitis: Further appraisal of immunosuppression post transplantation

European Journal of Gastroenterology and Hepatology

Volumn 17, Issue 12, 2005, Pages 1379-1385

  Ho, Gwo Tzer ^a,b   Seddon, Alexandra J ^a,b   Therapondos, George ^a   Satsangi, Jack ^b   Hayes, Peter C ^a  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^b WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Course; Immunosuppression; OLT; PSC; UC

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN A; MESALAZINE; METHYLPREDNISOLONE; SALAZOSULFAPYRIDINE; TACROLIMUS; URSODEOXYCHOLIC ACID;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CLINICAL ARTICLE; COLON RESECTION; CORTICOSTEROID THERAPY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DRUG DEPENDENCE; FEMALE; FOLLOW UP; GASTROINTESTINAL DYSPLASIA; GASTROINTESTINAL TUMOR; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; MALE; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; RECURRENCE RISK; TREATMENT OUTCOME; ULCERATIVE COLITIS;

ADULT; CHOLANGITIS, SCLEROSING; COLECTOMY; COLITIS, ULCERATIVE; DRUG ADMINISTRATION SCHEDULE; EPIDEMIOLOGIC METHODS; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSION; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; NEOPLASMS; POSTOPERATIVE CARE; RECURRENCE;

EID: 29244479987     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200512000-00018     Document Type: Article

References (34)

1. Chapman RW. The management of primary sclerosing cholangitis. Curr Gastroenterol Rep 2003; 5:9-17.
2. Tobias R, Wright JP, Kottler RE, Bornman PC, Price SK, Hatfield A, Marks IN. Primary sclerosing cholangitis associated with inflammatory bowel disease in Cape Town, 1. S Afr Med J 1983; 63:229-235.
3. Escorsell A, Pares A, Rodes J, SolisHerruzo JA, Miras M, de la Morena E. Epidemiology of primary sclerosing cholangitis in Spain. Spanish Association for the Study of the Liver. J Hepatol 1994; 21:787-791.
4. Goss JA, Shackleton CR, Farmer DG, Arnaout WS, Seu P, Markowitz JS, et al. Orthotopic liver transplantation for primary sclerosing cholangitis. A 12-year single center experience. Ann Surg 1997; 225:472-481.
5. Shetty K, Rybicki L, Carey WD. The Child-Pugh classification as a prognostic indicator for survival in primary sclerosing cholangitis. Hepatology 1997; 25:1049-1053.
6. Befeler AS, Lissoos TW, Schiano TD, Conjeevaram H, Dasgupta KA, Millis JM, et al. Clinical course and management of inflammatory bowel disease after liver transplantation. Transplantation 1998; 65:393-396.
7. Gavaler JS, Delemos B, Belle SH, Heyl AE, Tarter RE, Starzl TE, et al. Ulcerative Colitis Disease Activity as subjectively assessed by patient-completed questionnaires following orthotopic liver transplantation for sclerosing cholangitis. Dig Dis 1991; 321-328.
8. Miki C, Harrison JD, Gunson BK, Buckels JA, McMaster P, Mayer AD. Inflammatory bowel disease in primary sclerosing cholangitis: an analysis of patients undergoing liver transplantation. Br J Surg 1995; 82:1114-1117.
9. Papatheodoridis GV, Hamilton M, Mistry PK, Davidson B, Rolles K, Burroughs AK. Ulcerative colitis has an aggressive course after orthotopic liver transplantation for primary sclerosing cholangitis. Gut 1998; 43: 639-644.
10. Shaked A, Colonna JO, Goldstein L, Busuttil RW. The interrelation between sclerosing cholangitis and Ulcerative colitis in patients undergoing liver transplantation. Ann Surg 1992; 215:598-603.
11. Graziadei IW, Wiesner RH, Marotta PJ, Porayko MK, Hay JE, Charlton MR, et al. Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis. Hepatology 1999; 30:1121-1127.
12. Saldeen K, Friman S, Olausson M, Olsson R. Follow-up after liver transplantation for primary sclerosing cholangitis: effects on survival, quality of life, and colitis. Scand J Gastroenterol 1999; 34:535-540.
13. van der Vrie V, de Man RA, van Buuren HR, Schouten WR, Tilanus HW, Metselaar HJ. Inflammatory bowel disease and liver transplantation for primary sclerosing cholangitis. Eur J Gastroenterol Hepatol 2003; 15: 657-663.
14. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol 1989; 170:2-6.
15. Munkholm P, Langholz E, Davidsen M, Binder V. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 1994; 35:360-362.
16. Lundgrist K, Broome U. Differences in colonie disease activity in patients with primary sclerosing cholangitis. Dis Colon Rectum 2004; 40:1-6.
17. Higashi H, Yanaga K, Marsh JW, Tzakis A, Kakizoe S, Starzl TE. Development of colon cancer after liver transplantation for primary sclerosing cholangitis associated with ulcerative colitis. Hepatology 1990; 11:477-480.
18. Loftus EV Jr, Aguilar HI, Sandborn WJ, Tremaine WJ, Krom RA, Zinsmeister AR, et al. Risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis following orthotopic liver transplantation. Hepatology 1998; 27:685-690.
19. Soetikno RM, Lin OS, Heidenreich PA, Young HS, Blackstone MO. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Enclosc 2002; 56:48-54.
20. Bleday R, Lee E, Jessurun J, Heine J, Wong WD. Increased risk of early colorectal neoplasms after hepatic transplant in patients with inflammatory bowel disease. Dis Colon Rectum 1993; 36:908-912.
21. Narumi S, Roberts JP, Emond JC, Lake J, Ascher NL. Liver transplantation for sclerosing cholangitis. Hepatology 1995; 22:451-457.
22. Chapman RW. The colon and PSC: new liver, new danger? Gut 1998; 43:595-596.
23. Shibolet O, Regushevskaya E, Brezis M, Soares-Weiser K. Cyclosporine A for induction of remission in severe ulcerative colitis. Cochrane Database Syst Rev 2005; CD004277.
24. Sandborn WJ. Azathioprine: state of the art in inflammatory bowel disease. Scand J Gastroenterol Suppl 1998; 225:92-99.
25. Herrero JI, Lorenzo M, Quiroga J, Sangro B, Pardo F, Rotellar F, et al. De novo neoplasia after liver transplantation: an analysis of risk factors and influence on survival. Liver Transpl 2005; 11:89-97.
26. Herrero JI, Lucena JF, Quiroga J, Sangro B, Pardo F, Rotellar F, et al. Liver transplant recipients older than 60 years have lower survival and higher incidence of malignancy. Am J Transplant 2003; 3:1407-1412.
27. Xiol X, Guardiola J, Menendez S, Lama C, Figueras J, Marcoval J, et al. Risk factors for development of de novo neoplasia after liver transplantation. Liver Transpl 2001; 7:971-975.
28. Rutter M, Saunders B, Wilkinson K, Rumbles S, Schofield G, Kamm M, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004; 126:451-459.
29. Shetty K, Rybicki L, Brzezinski A, Carey WD, Lashner BA. The risk for cancer or dysplasia in ulcerative colitis patients with primary sclerosing cholangitis. Am J Gastroenterol 1999; 94:1643-1649.
30. Broome U, Lofberg R, Veress B, Eriksson LS. Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Hepatology 1995; 22:1404-1408.
31. Kornfeld D, Ekbom A, Ihre T. Is there an excess risk for colorectal cancer in patients with ulcerative colitis and concomitant primary sclerosing cholangitis? A population based study. Gut 1997; 41:522-525.
32. Marchesa P, Lashner BA, Lavery IC, Milsom J, Hull TL, Strong SA, et al. The risk of cancer and dysplasia among ulcerative colitis patients with primary sclerosing cholangitis. Am J Gastroenterol 1997; 92:1285-1288.
33. Brentnall TA, Haggitt RC, Rabinovitch PS, Kimmey MB, Bronner MP, Levine DS, et al. Risk and natural history of colonic neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 1996; 110:331-338.
34. D'Haens GR, Lashner BA, Hanauer SB. Pericholangitis and sclerosing cholangitis are risk factors for dysplasia and cancer in ulcerative colitis. Am J Gastroenterol 1993; 88:1174-1178.